CurrentBlue Cross Blue Shield - MassachusettsPolicy 562

Laser treatment for onychomycosis (coverage criteria)

Governs coverage and authorization for use of laser therapy to treat onychomycosis for Blue Cross Blue Shield Massachusetts members across commercial and Medicare products.

Policy Summary

PayerBlue Cross Blue Shield - Massachusetts

PolicyLaser treatment for onychomycosis (coverage criteria)

Policy CodePolicy 562

Change TypeNo material change

Effective DateNov 1, 2013

Next Review DateFeb 1, 2025

Key ActionObtain precertification/preauthorization when laser treatment for onychomycosis is performed inpatient.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

562Policy

InvestigationalCoverage stance

Inpatient PAPrecert required

Not coveredOutpatient status

InsufficientEvidence

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Coverage stance

Policy coverage determination for laser treatment of onychomycosis:

Investigational determination: Laser treatment of onychomycosis is considered investigational

Policy statement based on insufficient evidence that laser therapy improves net health outcomes

Outpatient coverage: Outpatient laser treatment is not a covered service for multiple listed commercial and Medicare products

Product-specific outpatient noncoverage noted in document

Prior authorization: Precertification/preauthorization is required if the procedure is performed inpatient

Operational requirement

For outpatient settings, laser treatment for onychomycosis is not a covered service for the products listed in this policy. This noncoverage applies to Commercial Managed Care (HMO and POS), Commercial PPO and Indemnity, and Medicare PPO BlueSM when the procedure is performed on an outpatient basis. Claims for outpatient laser treatment of onychomycosis for members in these product lines may be denied as not covered.

Laser treatment of onychomycosis is designated investigational because current evidence is insufficient to determine whether it improves net health outcomes. Systematic reviews and randomized controlled trials have reported inconsistent clinical and mycologic results, methodological limitations (including lack of consistent blinding and per‑nail analyses that did not account for correlated measurements), and imprecision in effect estimates. Because of these evidence gaps and potential publication bias, the policy does not cover laser therapy on the basis of investigational status.

Provider Requirements and Impact

Prior Authorization

Prior Authorization Required / Outpatient Noncoverage

Prior authorization/precertification is required for services described in this policy when performed in the inpatient setting. For outpatient services, laser treatment of onychomycosis is not a covered service for multiple commercial and Medicare products and may be denied if billed as outpatient without appropriate product-specific coverage. Providers should verify member-specific benefits and authorization requirements prior to scheduling.

Precertification/prior authorization required if performed inpatient for all products.
Outpatient laser treatment of onychomycosis: not a covered service for Commercial Managed Care (HMO and POS), Commercial PPO and Indemnity, and Medicare PPO BlueSM — claims may be denied.

Documentation Required

Required Coding and Diagnostic Documentation

Report all services using current, industry-standard procedure, revenue, and diagnosis codes; include applicable modifiers. There is no specific CPT code for laser treatment of onychomycosis. Submit diagnostic confirmation with the claim or precertification request (for example, KOH preparation, fungal culture, or histology) to support the medical necessity of treatment.

No specific CPT code exists for laser treatment of onychomycosis — use the most appropriate up-to-date procedure codes and modifiers.
Diagnostic confirmation required: potassium hydroxide (KOH) preparation, fungal culture, or histology should be documented and submitted.

Note

Alternative Therapies and Investigational Devices

Alternative and comparator therapies should be documented in the medical record. Topical antifungals (eg, ciclopirox, efinaconazole, tavaborole) and oral antifungals (eg, terbinafine, itraconazole; older agents such as griseofulvin) are established treatment options but have limitations (low-to-moderate efficacy, relapse risk, long treatment courses, potential hepatotoxicity with oral agents). Several device-based therapies (ultrasound, iontophoresis, photodynamic therapy, and various laser systems) are under investigation.

Document prior or concurrent use and response to topical and oral antifungal therapies when relevant.
Device-based therapies (ultrasound, iontophoresis, photodynamic therapy, laser systems) are investigational; include rationale if considering non-covered device treatments.

Denial Risk

Investigational Designation and Inpatient Precertification

Laser treatment of onychomycosis is designated investigational. Services performed without required authorization or services billed as outpatient where the product does not cover outpatient laser treatment may be denied. Providers should obtain inpatient precertification when applicable and confirm coverage for the member's specific product before providing treatment.

Investigational designation may lead to denial if no prior authorization is obtained.
Precertification required for inpatient services per product policy.

Definitions

Onychomycosis — key facts

DefinitionChronic fungal infection of the nail (toenails more often than fingernails).

Diagnostic confirmation methodsPotassium hydroxide (KOH) preparation, fungal culture, or histology to confirm the diagnosis.

Common causative organismsDermatophytes (eg, Trichophyton species), yeasts (eg, Candida albicans), and nondermatophytic molds; dermatophytes are most common in temperate Western countries.

Major risk factorsIncreasing age, diabetes, obesity, peripheral vascular disease, immunosuppression, and HIV infection.

Clinical impactCan cause pain, nail pressure, difficulty wearing shoes, and reduced quality of life; more severe cases may be associated with foot ulcer risk in diabetic patients.

Laser treatment for onychomycosis — device and mechanism

DescriptionDevice‑based therapy that applies specific wavelengths of laser light to nail and nail‑bed tissue to treat onychomycosis.

Mechanism (selective photothermolysis)Targets tissue with a specific wavelength so absorbed light generates heat in the target (nail bed) to disrupt fungal growth while sparing surrounding tissue.

Target temperatureAim is to heat the nail bed to temperatures sufficient to disrupt fungal growth (approximately 40–60°C).

Common laser systems/wavelengthsMost systems have been Nd:YAG lasers typically operating at 1064 nm; other reported wavelengths include ~940–1320 nm and 440 nm.

Advantages proposedGreater tissue penetration than topical agents and short clinical treatment courses (one or a few sessions) that may reduce reliance on prolonged patient compliance.

OpenPayer

Laser treatment for onychomycosis (coverage criteria)

Coverage Determination

Coding Guidance

Provider Requirements and Impact

Clinical Background

Definitions